Literature DB >> 20515504

An epidemiological investigation of leukemia incidence between 2003 and 2007 in Nanjing, China.

Bao-An Chen1, Zhi-Hu Huang, Xiao-Ping Zhang, Jian Ou-Yang, Jian-Yong Li, Yong-Ping Zhai, Xue-Mei Sun, Yan-Li Xu, Qin Lu, Jian-Min Wang, Dong Li, Hui Liao, Zhi-Xiang Shen, Yan-Yan Wang, Xiao-Jing Yu, Hui Ye, Li-Ying Zhuang.   

Abstract

BACKGROUND: There has been little literature about leukemia epidemiology in Nanjing in recent years. We aimed to explore the incidence rate, gender and age distribution of leukemia in Nanjing using the leukemia database of the city.
RESULTS: The average yearly incidence rate of leukemia was 3.68/105 during 2003 - 2007 in Nanjing. There were no significant difference in gender (x2 = 3.266, p > 0.05) or seasons (x2 = 11.36, p > 0.05). The incidence rate was the highest in group aged 80~ years (18.64/105). AML accounted for approximately 36.8% of all leukemias.
CONCLUSIONS: The incidence rate of leukemia, especially in the aged population, was relatively high in Nanjing. Leukemia is the major malignant tumor in children. Therefore, more attention should be paid to leukemia in children and the aged people.

Entities:  

Mesh:

Year:  2010        PMID: 20515504      PMCID: PMC2890531          DOI: 10.1186/1756-8722-3-21

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


To the Editor

Nanjing, an ancient capital and the second largest city in southeast China, enjoys a worldwide reputation for its long history and splendid culture. Little has been reported regarding leukemia epidemiology of the city in recent years. The present study was to investigate the leukemia incidence rate in Nanjing during 2003-2007, which may be of help to further leukemia etiology research. The leukemia data were collected from all hospitals which are capable of making a definite diagnosis of leukemia. We diagnosed leukemia by blood test, bone marrow puncture, histochemical staining and typing and classified by the "French American British" classification. The population data were provided by Nanjing Public Security Bureau and Nanjing Statistical Yearbook in 2007. There were 1,095 cases of various types of leukemia, while the total population in Nanjing during 2003-2007 was 29.7603 million, so the overall average annual incidence rate of leukemia was 3.68/105 and the age-standardized incidence rate was 3.47/105. The result was higher than that of the entire nation (2.76/105) [1], but lower than that in some other cities in China, such as: Shenyang(4.83/105) [2] and Tianjin during 1981-2000(4.71/105) [3]. Moreover, compared with the whites' leukemia incidence rate (12.8/105), it was lower. Table 1 shows incidence rates of all types of leukemia in every age group in Nanjing during 2003 to 2007. The leukemia incidence rate in old age groups was generally high, and reached to the peak in group aged 80~ years(18.64/105), but this was still lower than the highest rate in Shenyang-the group aged 75~ years (35.76/105) [2]. Although the incidence rate of leukemia in children was lower than that in the old age group, leukemia accounted for a big proportion in the child malignant tumors [2,4], therefore, leukemia has become the children's primary malignant tumor. The possibe explanation was bad internal environment's stable of hemopoiesis system in children, the hereditary factors, prenatal exposure to hazard factors of leukemia (X-ray, diesel oil, chemical fertilizer) and so on [5]. Other research presumed childhood leukemia was related with poor immunity and high birth weight [6].
Table 1

Leukemia subtype incidence between 2003 to 2007 for different age groups in Nanjing, China

Age (year)Rate(1/105)

AMLALLAULCLLCMLOtherTotal
0~0.492.950.490003.93
1~0.233.600.4600.1204.41
5~0.481.510.140.070.1402.34
10~0.770.680.140.100.051.74
15~0.431.060.0900.260.041.87
20~1.150.920.150.040.420.152.85
25~0.750.3700.040.4501.61
30~0.560.410.090.030.380.031.50
35~0.980.260.20.10.850.072.46
40~1.420.490.490.311.290.044.03
45~1.500.630.170.170.750.043.25
50~2.060.890.330.671.170.175.29
55~1.531.050.320.971.530.325.73
60~3.180.730.640.541.540.096.72
65~3.251.120.912.230.910.308.73
70~4.830.940.541.611.610.6710.20
75~4.681.491.284.682.340.4314.88
80~7.9900.446.213.110.8818.64
85~2.551.272.553.823.821.2715.29
Total1.350.810.270.410.730.113.68
composition ratio(%)36.822.17.319.711.22.9
Leukemia subtype incidence between 2003 to 2007 for different age groups in Nanjing, China Interestingly, AML accounted for approximately 25% of all leukemias in adults and 15%-20% in patients age ≤ 15 years in the Western world[7], which were both much lower than 36.8% in our research. The incidence rates of all types of leukemia especially non-AML types were lower in Nanjing. The composition ratio of different subtypes of AML were: M2(36.17%), M3(26.60%), M5(11.35%), M4(10.28%), M1(6.74%), M6(4.96%), M7(2.13%), M0(1.77%), respectively. These were similar to the reports in the literature [8,9]. By chi-square test, no significant difference was found between genders (x2 = 3.266, p > 0.05) or among seasons (x2 = 11.36, p > 0.05). And the 5-year incidence rate is relatviely stable. Current study has provided detailed information of the leukemia epidemiology in Nanjing during the period 2003-2007. Long-term follow-up investigations are needed for better understanding of characteristics of leukemia in Nanjing, including etiology, survival and risk indicators, which may lend support to the corresponding protocols for prevention and intervention.

Abbreviations

FAB: French-American-British Cooperation Group; ALL: acute lymphocytic leukaemia; AML: acute myeloid/myelogenous leukemia; CLL: chronic lymphocytic leukemia; CML: chronic myelocytic leukemia; AUL: acute unclassificatied leukemia.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Bao-An Chen, Zhi-Hu Huang and Xiao-Ping Zhang collected the data and contributed to analysis and writing. Jian Ou-Yang, Jian-Yong Li, Yong-Ping Zhai, Xue-Mei Sun, Yan-Li Xu, Qin Lu, Jian-Min Wang, Dong Li, Hui Liao, Zhi-Xiang Shen, Yan-Yan Wang collected the data. Xiao-Jing Yu, Hui Ye, Li-Ying Zhuang did the statistical analyses.
  3 in total

1.  Childhood leukaemia and exposure to pesticides: results of a case-control study in northern Germany.

Authors:  R Meinert; P Kaatsch; U Kaletsch; F Krummenauer; A Miesner; J Michaelis
Journal:  Eur J Cancer       Date:  1996-10       Impact factor: 9.162

2.  Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project.

Authors:  J W W Coebergh; A M J Reedijk; E de Vries; C Martos; Z Jakab; E Steliarova-Foucher; W A Kamps
Journal:  Eur J Cancer       Date:  2006-09       Impact factor: 9.162

3.  Evidence on the infectious etiology of childhood leukemia: the role of low herd immunity (Greece).

Authors:  E Petridou; M Dalamaga; A Mentis; A Skalkidou; M Moustaki; T Karpathios; D Trichopoulos
Journal:  Cancer Causes Control       Date:  2001-09       Impact factor: 2.506

  3 in total
  7 in total

Review 1.  Acute myeloid leukemia of a primary hepatic carcinoma patient after liver transplantation: a case report and literature review.

Authors:  Wen-Jun Wu; Meng-Meng Dong; Yun Chen; Jing-Song He; He Huang; Zhen Cai
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.

Authors:  Xiaofei Zhou; Sharon Friedlander; Erik Kupperman; Farhad Sedarati; Shingo Kuroda; Zhaowei Hua; Ying Yuan; Yuka Yamamoto; Douglas V Faller; Kazue Haikawa; Katsuhiko Nakai; Sharon Bowen; Yi Dai; Karthik Venkatakrishnan
Journal:  Clin Transl Sci       Date:  2021-02-02       Impact factor: 4.689

3.  The Profile of T Helper Subsets in Bone Marrow Microenvironment Is Distinct for Different Stages of Acute Myeloid Leukemia Patients and Chemotherapy Partly Ameliorates These Variations.

Authors:  Tian Tian; Shuang Yu; Lu Liu; Fuzhong Xue; Cunzhong Yuan; Min Wang; Chunyan Ji; Daoxin Ma
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

4.  MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis.

Authors:  Qiang Guo; Junwen Luan; Ni Li; Zhen Zhang; Xiaoxiao Zhu; Lin Zhao; Ran Wei; Linlin Sun; Yin Shi; Xunqiang Yin; Na Ding; Guosheng Jiang; Xia Li
Journal:  Oncotarget       Date:  2017-07-12

5.  Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.

Authors:  Li Ye; Lingsu Gao; Qiansong Cheng; Feng Guo; Liang He; Tingting Yuan; Ming Zhu; Yuanfang Ma; Min Pan; Xiandeng Chu; Meiqi Ding; Guohui Yu
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

6.  Ethnicity-stratified analysis of the association between XRCC3 Thr241Met polymorphism and leukemia: an updated meta-analysis.

Authors:  Zhengjun Xie; Wei Peng; Qiuhua Li; Wei Cheng; Xin Zhao
Journal:  BMC Med Genomics       Date:  2021-09-18       Impact factor: 3.063

7.  Estimating the burden of fungal disease in Vietnam.

Authors:  J Beardsley; D W Denning; N V Chau; N T B Yen; J A Crump; J N Day
Journal:  Mycoses       Date:  2015-10       Impact factor: 4.377

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.